Merck CEO focuses on acquisitions; Alkermes lays plans for ALKS8700 NDA for MS;

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Interesting that most of the $PFE/$AGN discussion is around the mechanics of a deal, rather than a backlash against another megamerger. | Follow @JohnCFierce

> Merck ($MRK) CEO Ken Frazier is sounding distinctly more bullish about new biotech acquisitions in the wake of the market correction for the sector. "We have seen values go down over these last few weeks and we're going to continue to look for those opportunities," Frazier told analysts. Story

> Alkermes ($ALKS) says it's on track to file its MS drug ALKS8700 in 2018. "With these positive pharmacokinetic bridging results and agreement with the FDA on our regulatory strategy in hand, our path to approval for ALKS 8700 has been clarified. A key component of the program is the comparison of GI tolerability, as we see this as an opportunity to potentially provide new benefits to MS patients," said Elliot Ehrich, the CMO at Alkermes. "We remain on track to advance ALKS 8700 twice-daily into Phase 3 development with the initiation of the two-year safety study later this year, and we plan to file the NDA in 2018." Release

Medical Device News

@FierceMedDev: Cleveland Clinic developing catheter for delivery of chemotherapy directly into the brain. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Theranos authorized new shares that would value the co. at $10B, 3 days before the WSJ article came out. Story | Follow @EmilyWFierce

> Startup Qvella gets $20M Series A to develop rapid pathogen detection test. Story

> Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. News

Pharma News

@FiercePharma: Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: IOYMI: Napp Pharmaceuticals says it is offering England's NHS Remsima for as much as 60% less than Remicade. Article | Follow @EricPFierce

@CarlyHFierce: GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge. Article | Follow @CarlyHFierce

> Sanofi's Q3 bombshell: Diabetes sales drop, and will keep dropping through 2018. More

> Q3 beats on sales, earnings ready Amgen for biosimilar attack. Story

> Shopping for a tax-friendly megamerger, Pfizer zeroes in on self-styled 'growth pharma' Allergan. Article

CRO News

> Icon ekes out another quarter of growth despite currency woes. More

> INC boosts its outlook after another big revenue quarter. Report

> Parexel's profits slide as it slashes costs. Story

> Novartis, Qualcomm back trial startup's $6.5M round. Item

> PRA upgrades its Dutch R&D hub with eyes on bioanalytics. Article

Pharma Manufacturing News

> Pfizer and GSK to work together on continuous manufacturing. Item

> Novartis' Sandoz plants in India cited in warning letter. More

> Saline producers face call for FTC probe into shortage, rising prices. Report

> States want FDA to quit seizing their execution drugs. Story

> Aurobindo moves forward with plans for new U.S. plant. Article

Pharma Asia News

> Novartis to close one Indian manufacturing plant as FDA warning bites. Article

> Lupin hopes for more U.S. approvals as earnings drop 35%. Item

> Health insurance companies still being targeted by Chinese hackers. Story

> Cough syrup abuse gets India's attention. More

> BMS sees sharper hep C competition in Japan in Q3. Report

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.